近期，起源于印度的跨国药企Intas Pharmaceuticals子公司Accord Plasma B.V.宣布已签署协议，将全资收购Prothya Biosolutions Belgium BV及其所有子公司。此次拟议的收购标志着Intas & Accord朝着在PDMP市场建立全球影响力的长期雄心目标迈出了重要一步，从而将Intas在印度市场的既有领先地位拓展至真正的国际化版图。
Prothya Biosolutions在阿姆斯特丹和布鲁塞尔开展主要业务，并在匈牙利各地设有血浆采集中心，拥有约1,200名员工。 该公司是欧洲最大的血浆分离企业之一。 Prothya成立于2021年，由原隶属于比利时红十字会的Plasma Industries Belgium和原属Sanquin Blood Supply Foundation的Sanquin Plasma Products合并而成，在血浆采集与PDMP研发领域拥有超过60年的经验。
上海因特普林翻译新闻内容如下：
Ahmedabad, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma - derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly.
This proposed acquisition marks a significant step in Intas and Accord's long - standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in India into a truly international footprint.
Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe's largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs.
" We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform — serving patients worldwide with critical, often under - prescribed, therapies. "
Intas's plasma division in India has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat - based facility.
" Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world's leading PDMP companies — all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion. "
The global market for PDMPs — particularly IVIG (intravenous immunoglobulin) — is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries.
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end - to - end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs.
子馨
15618628760